Amedisys, Inc. (NASDAQ:AMED) Shares Sold by Rothschild & Co. Asset Management US Inc.

Rothschild & Co. Asset Management US Inc. reduced its position in Amedisys, Inc. (NASDAQ:AMEDGet Rating) by 22.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,964 shares of the health services provider’s stock after selling 9,262 shares during the quarter. Rothschild & Co. Asset Management US Inc. owned approximately 0.10% of Amedisys worth $5,507,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Swiss National Bank grew its position in Amedisys by 7.2% in the 1st quarter. Swiss National Bank now owns 77,100 shares of the health services provider’s stock valued at $13,284,000 after acquiring an additional 5,200 shares in the last quarter. TD Asset Management Inc. grew its position in shares of Amedisys by 113.0% during the fourth quarter. TD Asset Management Inc. now owns 25,252 shares of the health services provider’s stock worth $4,088,000 after buying an additional 13,394 shares in the last quarter. Icon Wealth Partners LLC grew its position in shares of Amedisys by 194.4% during the first quarter. Icon Wealth Partners LLC now owns 8,627 shares of the health services provider’s stock worth $1,486,000 after buying an additional 5,697 shares in the last quarter. Frontier Capital Management Co. LLC grew its position in shares of Amedisys by 98.3% during the first quarter. Frontier Capital Management Co. LLC now owns 340,741 shares of the health services provider’s stock worth $58,706,000 after buying an additional 168,949 shares in the last quarter. Finally, Gotham Asset Management LLC grew its position in shares of Amedisys by 3.5% during the fourth quarter. Gotham Asset Management LLC now owns 11,168 shares of the health services provider’s stock worth $1,808,000 after buying an additional 381 shares in the last quarter. 93.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on AMED. Cowen lowered their price objective on Amedisys to $125.00 in a research report on Tuesday, August 9th. Oppenheimer lowered their price objective on Amedisys from $200.00 to $175.00 in a research report on Friday, July 29th. UBS Group downgraded Amedisys from a “neutral” rating to a “sell” rating and lowered their price objective for the stock from $145.00 to $95.00 in a research report on Tuesday, August 2nd. Stephens lowered their price objective on Amedisys from $155.00 to $125.00 and set an “equal weight” rating for the company in a research report on Tuesday, June 21st. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on Amedisys from $210.00 to $175.00 and set a “buy” rating for the company in a research note on Tuesday, June 21st. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and ten have given a buy rating to the stock. According to MarketBeat, Amedisys presently has a consensus rating of “Hold” and a consensus price target of $158.53.

Amedisys Price Performance

Shares of NASDAQ AMED opened at $123.80 on Friday. The company has a current ratio of 0.92, a quick ratio of 0.92 and a debt-to-equity ratio of 0.43. Amedisys, Inc. has a twelve month low of $101.61 and a twelve month high of $188.88. The stock has a 50 day moving average of $121.35 and a two-hundred day moving average of $131.96. The stock has a market cap of $4.02 billion, a P/E ratio of 28.86, a P/E/G ratio of 2.77 and a beta of 0.95.

Amedisys (NASDAQ:AMEDGet Rating) last issued its quarterly earnings data on Wednesday, July 27th. The health services provider reported $1.47 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.24. Amedisys had a return on equity of 17.81% and a net margin of 6.33%. The company had revenue of $557.89 million during the quarter, compared to analysts’ expectations of $583.12 million. During the same quarter in the previous year, the business earned $1.69 earnings per share. The firm’s revenue for the quarter was down 1.1% on a year-over-year basis. On average, research analysts forecast that Amedisys, Inc. will post 5.34 earnings per share for the current year.

Insider Buying and Selling at Amedisys

In other Amedisys news, insider Denise M. Bohnert sold 557 shares of the business’s stock in a transaction that occurred on Thursday, June 23rd. The stock was sold at an average price of $115.00, for a total value of $64,055.00. Following the completion of the sale, the insider now owns 11,850 shares in the company, valued at $1,362,750. The sale was disclosed in a document filed with the SEC, which is available through this link. 2.10% of the stock is owned by company insiders.

Amedisys Company Profile

(Get Rating)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Read More

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.